You need to create a user account to read this article.
With a subscription you unlock more content on BioStock.
It has sometimes felt disconsolate to wander through the biotech sector's wolf winter. A barren capital raising landscape has offered strong headwinds that have often thrown snow in the face of the investor. After three difficult...
Previous chronicles
The generalists about to jump on the bandwagon
Pfizer’s whining confirm it – Metsera is the perfect fit for Novo
All power to Sørensen – more turbulence ahead
Biotech shows increasing signs of life – is there more upside?
Big pharma ditches the UK – A stark warning
Is Nordic life science on sale?
Springtime for biotech – the thaw has begun
Integrum’s fiasco: a stain on a good record
Novo takes first step – now the market will pass its judgment
Founders cash in – is it time to sell BioArctic?
You deserve the best!
Unlock our premium content: Become a subscriber!
Create Account